卡瑞利珠单抗联合同步放化疗治疗晚期宫颈癌患者的临床效果
Clinical effect of Camrelizumab combined with concurrent chemo-radiotherapy in the treatment of patients with advanced cervical cancer
杜丽文1
作者信息
- 1. 山东省兰陵县人民医院肿瘤放疗科,山东兰陵 277700
- 折叠
摘要
目的 探讨卡瑞利珠单抗联合同步放化疗治疗晚期宫颈癌患者的临床效果.方法 选取 2020 年1月至 2022 年1月山东省兰陵县人民医院肿瘤放疗科收治的 50 例晚期宫颈癌患者,采用随机抽签法分为对照组(25 例,同步放化疗)、研究组(25 例,卡瑞利珠单抗联合同步放化疗),比较两组治疗效果、不良反应发生情况.结果 研究组治疗总有效率为 88.00%,高于对照组的 64.00%(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05).结论 卡瑞利珠单抗联合同步放化疗治疗晚期宫颈癌患者的临床效果较好,能够提高治疗有效率,且不会增加不良反应.
Abstract
Objective To investigate the clinical effect of Camrelizumab combined with concurrent chemoradiotherapy in the treatment of patients with advanced cervical cancer.Methods A total of 50 patients with advanced cervical cancer admitted to the Department of Radiation Oncology,Lanling County People's Hospital of Shandong Province from January 2020 to January 2022 were selected.They were randomly divided into control group(25 cases,concurrent chemoradiotherapy)and study group(25 cases,Camrelizumab combined with concurrent chemoradiotherapy).The treatment effect and adverse reactions were compared between the two groups.Results The total effective rate of the study group was 88.00%,which was higher than 64.00%of the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Camrelizumab combined with concurrent chemoradiotherapy has a good clinical effect in the treatment of patients with advanced cervical cancer,which can improve the treatment efficiency without increasing adverse reactions.
关键词
卡瑞利珠单抗/同步放化疗/晚期宫颈癌Key words
Camrelizumab/Concurrent chemoradiotherapy/Advanced cervical cancer引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据